These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28494506)

  • 21. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
    J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
    Leroy H; de Botton S; Grardel-Duflos N; Darre S; Leleu X; Roumier C; Morschhauser F; Lai JL; Bauters F; Fenaux P; Preudhomme C
    Leukemia; 2005 Mar; 19(3):367-72. PubMed ID: 15674426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
    Zhu HH; Zhang XH; Qin YZ; Liu DH; Jiang H; Chen H; Jiang Q; Xu LP; Lu J; Han W; Bao L; Wang Y; Chen YH; Wang JZ; Wang FR; Lai YY; Chai JY; Wang LR; Liu YR; Liu KY; Jiang B; Huang XJ
    Blood; 2013 May; 121(20):4056-62. PubMed ID: 23535063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
    Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
    Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)].
    Gritsaev SV; Martynkevich IS; Ziuzgin IS; Kariagina EV; Martynenko LS; Petrova EV; Tsybakova NIu; Ivanova MP; Kostroma II; Tiranova SA; Potikhonova NA; Abdulkadyrov KM
    Ter Arkh; 2014; 86(7):45-52. PubMed ID: 25314777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
    Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia.
    Yucel OK; Alemdar MS; Atas U; Undar L
    Chemotherapy; 2020; 65(5-6):166-170. PubMed ID: 33316797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K; Ohnishi K
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
    Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M
    Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Gabellier L; Peterlin P; Thepot S; Hicheri Y; Paul F; Gallego-Hernanz MP; Bertoli S; Turlure P; Pigneux A; Guieze R; Ochmann M; Malfuson JV; Cluzeau T; Thomas X; Tavernier E; Jourdan E; Bonnet S; Tudesq JJ; Raffoux E
    Ann Hematol; 2024 Mar; 103(3):759-769. PubMed ID: 38273140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
    Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
    J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?
    Yoon S; Kim H; Hur M; Han SH; Chung HJ; Moon HW; Yun YM; Lee MH
    Int J Lab Hematol; 2019 Dec; 41(6):e145-e147. PubMed ID: 31050862
    [No Abstract]   [Full Text] [Related]  

  • 39. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.
    Nanah R; McCullough K; Hogan W; Begna K; Patnaik M; Elliott M; Litzow M; Al-Kali A
    Am J Hematol; 2017 Sep; 92(9):866-871. PubMed ID: 28474744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
    Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.